Anti-Respiratory Syncytial Virus (Clone: RSV-12I1)
Roll over image to zoom in
Shipping Info:
For estimated delivery dates, please contact us at [email protected]
| Amount : | 100 µg |
| Isotype : | Human IgG1λ |
| Purification : | ≥95% monomer by analytical SEC |
| Content : | ≥ 5.0 mg/ml. This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. |
| Storage condition : | Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one year. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≥ -70°C. Avoid Repeated Freeze Thaw Cycles. |
| Alternative Name : | RSV, Orthopneumovirus |
| Immunogen Information : | Human donors targeting the post-fusion RSV F protein using human hybridoma technology |
Reactivity Species : Respiratory Syncytial⋅Virus
Expression Host : HEK-293
Endotoxin Level : ≤ 1.0 EU/mg as determined by the LAL method
Specificity : RSV-12I1 activity is directed against antigenic site II of the RSV fusion (F) protein.
Clone RSV-12I1 did bind to both pre- and post-fusion F protein in an ELISA binding assay, favoring the post-fusion conformation. Competition-binding studies showed that RSV-12I1 targets antigenic site II, which is the target of palivizumab, an antiviral monoclonal antibody licensed as a prophylactic treatment. RSV-12I1 readily competed with RSV-14N4 on post-fusion F, but the competition was less pronounced on pre-fusion F. RSV-12I1 also competed with palivizumab on post-fusion F in a palivizumab competition assay. Saturation alanine scanning mutagenesis identified residues Leu467 and Lys470 as critical for RSV-12I1 binding. Binding was not detected to scaffolded epitopes containing site II.
|
There are currently no product reviews
|
.png "ACE2/HEK293 Stable Cell Line")
